# Anti-Androgen Treatment for COVID-19

> **NCT04446429** · NA · COMPLETED · sponsor: **Applied Biology, Inc.** · enrollment: 268 (actual)

## Conditions studied

- COVID-19
- SARS-CoV2
- Androgenetic Alopecia
- Prostate Cancer
- Benign Prostatic Hyperplasia
- SARS (Severe Acute Respiratory Syndrome)

## Interventions

- **DRUG:** Proxalutamide
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04446429
- **Lead sponsor:** Applied Biology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-21
- **Primary completion:** 2020-12-24
- **Final completion:** 2021-01-21
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2021-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04446429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04446429, "Anti-Androgen Treatment for COVID-19". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04446429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*